MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Total Current Liabilities
All obligations due within one year.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 10.0% from a year ago
Total current liabilities stood at $14.28M at the end of Q1 FY2026, up 10.0% from a year earlier and down 12.0% from the prior quarter. Over 3 fiscal years it compounded at +8.8% a year.
Context
- Total current liabilities amounted to 3.4% of total assets at the end of Q1 FY2026, down 8.2 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +10.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 16.23M USD
- Year-over-year change
- +1.9%
- 3-year CAGR
- +8.8%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.23M | +1.9% |
| FY2024 | 2024-12-31 | 15.92M | +8.3% |
| FY2023 | 2023-12-31 | 14.7M | +16.7% |
| FY2022 | 2022-12-31 | 12.6M | — |
Total Current Liabilities vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 total current liabilities of $14.28M is the 7th highest of the 11 companies compared; the peer median is $16.82M.
- Its year-over-year change of +10.0% is the 8th highest of 11, against a peer median of +71.8%.
- Total current liabilities amounts to 3.4% of total assets for MPLT, versus a peer median of 4.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.96B | +156415.7% | +18.5% | 4.2% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $67.73M | +3.5% | +55.1% | 6.3% |
| Mar 2026 | $47.03M | +74.3% | +48.4% | 16.9% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $30.12M | +6.1% | +11.0% | 19.6% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $17.9M | +90.7% | +125.4% | 3.6% |
| Mar 2026 | $15.75M | +69.2% | +5.8% | 7.0% | |
| Mar 2026 | $14.28M | +10.0% | +8.8% | 3.4% | |
| Mar 2026 | $13.12M | +80.7% | +26.8% | 4.7% | |
| Mar 2026 | $11.82M | +19.1% | +22.6% | 4.3% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $10.91M | +179.2% | +151.3% | 2.8% |
| Dec 2025 | $6.37M | -51.5% | -4.3% | 4.8% | |
| Peer median (excluding MPLT) | $16.82M | +71.8% | +24.7% | 4.8% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.